Background
Methods
Searching
Study selection and characteristics
Validity assessment
Data abstraction
Quantitative data synthesis
Results
Trial flow / flow of included studies
RCTs
Study characteristics
Interventions | Study | Study design | N* | Age median (range) | Males (%) | Median duration of follow-up (weeks) | Prior therapy for advanced disease | Performance status, n (%) | STS subtypes, (%) |
---|---|---|---|---|---|---|---|---|---|
Pazopanib 800 mg per day orally | R, DB, PC, MC-I, Phase III | 246 | 56.0 (20.0-83.0) | 40.0% | 49.5 weeks | Anthracycline: 98.8%; ifosfamide: 66.7% | PS 0: 118 (48.0); PS 1: 128 (52.0) | Leiomyosarcoma: 44.3%; Synovial sarcoma: 10.2%; Others: 45.5% | |
Placebo | 123 | 51.0 (18.0-78.0) | 44.0% | 45.3 weeks | Anthracycline: 98.4%; ifosfamide: 75.6% | PS 0: 60 (48.8); PS 1: 67 (51.2) | Leiomyosarcoma: 39.8%; Synovial sarcoma: 10.6%; Others: 49.6% | ||
Trabectedin 1.5 mg/m2 24-hour infusion q3w | R, OL, DR, MC-I, Phase II | 136 | 53 (20–80) | 32.4% | 177.67 weeks | Anthracycline: 100%; anthracycline and ifosfamide: 99.3% | PS 0: 70 (51.5); PS 1: 66 (48.5) | Leiomyosarcoma: 61.5%; Liposarcoma: 25.6%; Others: 12.8% | |
Trabectedin 0.58 mg/m2 3-hour infusion qw | 134 | 54 (23–77) | 41.8% | PS 0: 67 (50.0); PS 1: 67 (50.0) | Leiomyosarcoma: 55.5%; Liposarcoma: 37.8%; Others: 6.7% | ||||
Gemcitabine 1800 mg/m2 as a fixed dose infusion rate (10 mg/m2/minutes) + dacarbazine 500 mg/m2 q2w | R, BU, AC, MC, Phase II | 59 | 49 (18–78) | 53.0% | 62.83 weeks | Out of total eligible population of 109 patients 107 patients had received anthracycline and two patients had received ifosfamide | PS 0:22 (38.6); PS 1:30 (52.6); PS 2:5 (8.8) | Leiomyosarcoma: 28.1%; Liposarcoma/adipocytic sarcoma: 17.5%; Undifferentiated pleomorphic: 19.3%; Miscellaneous sarcoma: 24.6%; Synovial sarcoma: 10.5% | |
Dacarbazine 1200 mg/m2 q3w | 54 | 51 (25–73) | 54.0% | 60.67 weeks | PS 0: 17 (32.7); PS 1: 31 (51.6); PS 2: 4 (7.7) | Leiomyosarcoma: 30.8%; Liposarcoma/adipocytic sarcoma: 17.3%; Undifferentiated pleomorphic: 15.4%; Miscellaneous sarcoma: 26.9%; Synovial sarcoma: 9.6% | |||
Gemcitabine 900 mg/m2 over 90 minutes, D1+D8 + docetaxel 100 mg/m2 over 60 min, D8 q21 days | R, BU, AC, MC, Phase II | 84** | - | - | Unclear | Anthracycline: 100% | - | Leiomyosarcoma: 100% | |
Gemcitabine 1000 mg/m2 over 100 minutes, d1+d8+d15 q28 days | - | - | Anthracycline: 100% | - | Leiomyosarcoma: 100% | ||||
Sorafenib 400 mg twice daily orally | Pacey 2011 [28] | R, DB, PC, MC-I, Phase II | 2 | - | - | Unclear | Anthracycline and/or ifosfamide: 100% | - | Fibrosarcoma: 0.0% |
Placebo | Pacey 2011 [28] | 2 | 67 (62–72) | 0 | PS 0: 2 (100) | Leiomyosarcoma: 50.0%; Fibrosarcoma: 50.0% | |||
PS 1: 0 (0.0) | |||||||||
Ifosfamide 5 g/m2/1 day given as 24-hour infusion; all cycles were repeated q3w | van Oosterom 2002 [29] | R, BU, DR, MC-I, Phase II | 27 | - | - | Unclear | Anthracycline: 100% | - | - |
Ifosfamide 3 g/m2/day given over 4 hour on 3 consecutive days; all cycles were repeated q3w | van Oosterom 2002 [29] | 31 | - | - | Anthracycline: 100% | - | - |
Efficacy/activity results
Intervention | Study | N | Progression free survival | Overall survival | Response rate | Progressive disease | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PFS rate, n (%) | PFS in months | 1 year OS | OS in months | ORR | CR | PR | SD | PD | ||||
3-month | 6-month | median (95% CI) | n (%) | median (95% CI) | n (%) | n (%) | n (%) | n (%) | n (%) | |||
Pazopanib | PALETTE study 2011/2 | 246 | - | - | 4.6† | - | 12.6 | 11 (4.5) † | 0 (0.0) † | 11 (4.5) † | 134 (54.5)† | 66 (26.8) † |
Placebo | PALETTE study 2011 | 123 | - | - | 1.6† | - | 10.7 | 0 (0.0) † | 0 (0.0) † | 0 (0.0) † | 33 (26.8) † | 76 (61.8) † |
Trabectedin 1.5 mg/m2 q3w | Demetri 2009 | 136 | 70 (51.5) | 48 (35.5) | 3.3† (2.1 - 4.6) | 82 (60.0) | 13.9 (12.5 - 18.6) | 8 (5.6)† | - | - | - | - |
Trabectedin 0.58 mg/m2 qw | Demetri 2009 | 134 | 60 (44.7) | 37 (27.5) | 2.3† (2.0 - 3.4) | 67 (50.0) | 11.8 (9.9 - 14.9) | 2 (1.6)† | - | - | - | - |
Dacarbazine | GEIS study | 54 | 19 (35.2); p=0.001 | - | 2.0# | - | 8.2§ | 2 (3.7)‡, p=0.16 | - | 2 (4.0)*# | 10 (19.0)*# | - |
Gemcitabine + Dacarbazine | GEIS study | 59 | 32 (54.2); p=0.001 | - | 4.2# | - | 16.8§ | 7 (11.9)‡, p=0.16 | - | 5 (9.0)* # | 22 (38.0)*# | - |
Sorafenib | Pacey 2011 | 2 | - | - | - | - | - | - | - | - | - | 0 (0.0) # |
Placebo | Pacey 2011 | 2 | - | - | - | - | - | - | - | 0 (0.0) # | 2 (100) # | 0 (0.0) # |
Gemcitabine | Pautier 2009 | - | - | - | - | - | - | - | - | - | - | - |
Gemcitabine + Docetaxel | Pautier 2009 | - | - | - | - | - | - | - | - | - | - | - |
Ifosfamide 5 g/m2/day | van Oosterom 2002 | 27 | - | - | - | - | - | - | - | - | - | - |
Ifosfamide 3 g/m2/day | van Oosterom 2002 | 31 | - | - | - | - | - | - | - | - | - | - |
Phase III trials
Phase II trials
Safety results
AEs by class | PALETTE study 2011#
| Demetri 2009 | GEIS study 2011 | Pautier 2009 | Pacey 2011* | van Oosterom 2002 | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Pazopanib, n (%) | Placebo, n (%) | Trabectedin 1.5 mg/m2 q3w, n (%) | Trabectedin 0.58 mg/m2 qw, n (%) | Dacarbazine, n (%) | Gemcitabine + Dacarbazine, n (%) | Gemcitabine, n (%) | Gemcitabine + Docetaxel, n (%) | Placebo, n (%) | Sorafenib, n (%) | Ifosfamide 5 g/m2/day, n (%) | Ifosfamide 3 g/m2/day, n (%) | |
Evaluable N | 240 | 123 | 130 | 130 | 52 | 57 | - | - | 2 | 2 | 27 | 31 |
GI disorders
| ||||||||||||
Abdominal pain | 0 (0.0) | 0 (0.0) | 6 (4.6) | 6 (4.6) | - | - | - | - | - | - | - | - |
Constipation | 1 (0.4) | 3 (2.4) | 0 (0.0) | 2 (1.5) | - | - | - | - | - | - | - | - |
Diarrhoea | 11 (4.6) | 1 (0.8) | 1 (0.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | - | - | - | - | - |
GI pain | 6 (2.5) | 5 (4.1) | - | - | - | - | - | - | - | - | - | - |
Mucositis/stomatitis | 1 (0.4) | 0 (0.0) | - | - | 0 (0.0) | 1 (1.8) | - | - | - | - | - | - |
Nausea | 8 (3.3) | 2 (1.6) | 7 (5.4) | 3 (2.3) | 1 (1.9)~ | 0 (0.0)~ | - | - | - | - | - | - |
Nausea/vomiting | - | - | - | - | - | - | - | - | - | - | 0 (0.0)$ | - |
Vomiting | 8 (3.3) | 1 (0.8) | 7 (5.4) | 2 (1.5) | 0 (0.0)~ | 1 (1.8)~ | - | - | - | - | - | - |
Small intestinal obstruction | 3 (1.3) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
General disorders
| ||||||||||||
Asthenia | 0 (0.0) | 0 (0.0) | - | - | 5 (9.6)~ | 4 (7.0)~ | - | - | - | - | - | |
Back pain | - | - | 4 (3.1) | 4 (3.1) | - | - | - | - | - | - | - | - |
Fatigue | 33 (13.7) | 6 (4.9) | 10 (7.7) | 9 (6.9) | - | - | - | - | - | - | - | - |
Peripheral oedema | 5 (2.1) | 2 (1.6) | - | - | - | - | - | - | - | - | - | - |
Chest pain | 4 (1.7) | 0 (0.0) | ||||||||||
Skin and subcutaneous tissues disorders
| ||||||||||||
Skin disorder | 4 (1.7) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Investigations
| ||||||||||||
ALT increased | 23 (9.6) | 4 (3.3) | 62 (47.7) | 12 (9.2) | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Alkaline phosphatase | 7 (2.9) | 1 (0.8) | 2 (1.5) | 3 (2.3) | - | - | - | - | - | - | - | - |
AST increased | 19 (7.9) | 2 (1.6) | 41 (31.5) | 4 (3.1) | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Creatinine increased | 1 (0.4) | 0 (0.0) | 3 (2.3) | 1 (0.8) | - | - | - | - | - | - | - | - |
Creatinine phosphokinase | - | - | 7 (5.4) | 12 (9.2) | - | - | - | - | - | - | - | - |
Bilirubin increased | 3 (1.3) | 2 (1.6) | 1 (0.8) | 1 (0.8) | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Gamma-glutamyltransferase | 4 (1.7) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Weight loss | 9 (3.8) | 0 (0.0) | - | - | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
ENT examination abnormal | 4 (1.7) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Hypoalbuminemia | - | - | - | - | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Hemorrhagic events
| ||||||||||||
Hemorrhagic event (any) | 5 (2.0) | 2 (1.6) | - | - | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Metabolism and nutrition disorders
| ||||||||||||
Decreased appetite | 14 (5.9) | 0 (0.0) | 1 (0.8) | 0 (0.0) | - | - | - | - | - | - | - | - |
Dehydration | 3 (1.4) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Musculoskeletal and connective tissue disorders
| ||||||||||||
Arthralgia/myalgia | 5 (2.1) | 0 (0.0) | - | - | - | - | - | - | 0 (0.0) | 0 (0.0) | - | - |
Musculoskeletal pain | 5 (2.1) | 2 (1.6) | - | - | - | - | - | - | - | - | - | - |
Respiratory, thoracic, and medistinal disorders
| ||||||||||||
Dyspnoea | 15 (6.3) | 7 (5.7) | 5 (3.8) | 8 (6.2) | - | - | - | - | - | - | - | - |
Pleural effusion | 5 (2.1) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Blood and lymphatic system disorders
| ||||||||||||
Anaemia | 15 (6.3) | 2 (1.6) | 10 (7.7) | 12 (9.2) | 6 (11.5) | 2 (3.5) | - | - | - | - | - | - |
Febrile neutropenia | - | - | - | - | 3 (5.8) | 5 (8.8) | - | - | - | - | - | - |
Leukopenia | 3 (1.3) | 0 (0.0) | - | - | 16 (30.8) | 15 (26.3) | - | - | - | - | - | - |
Neutropenia | 10 (4.2) | 0 (0.0) | 61 (46.9) | 17 (13.1) | 17 (32.7) | 27 (47.4) | - | - | - | - | - | - |
Thrombocytopenia | 9 (3.8) | 0 (0.0) | 15 (11.5) | 7 (5.4) | 14 (26.9) | 3 (5.3) | - | - | - | - | 0 (0.0)$ | - |
Lymphopenia | 23 (9.6) | 13 (10.6) | - | - | - | - | - | - | - | - | - | - |
Cardiac disease
| ||||||||||||
Hypertension | 16 (6.7) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Myocardial/LVEF Dysfunction | 4 (1.7) | 0 (0.0) | - | - | - | - | - | - | - | - | - | - |
Other disorders
| ||||||||||||
Tumour pain | 20 (8.3) | 9 (7.3) | ||||||||||
Non-haemotological | - | - | - | - | - | - | - | 2¶ | - | - | - | - |
Treatment discontinuations
Intervention | Study | N | Treatment discontinuation, n (%) | Most common AEs leading to discontinuations | ||||||
---|---|---|---|---|---|---|---|---|---|---|
All | Due to AE | Due to death | Due to PD | Due to lost to follow-up | Due to patient decision | Due to other reasons | ||||
Pazopanib | PALETTE study 2011/2 | 246 | 240 (97.6) | 41 (16.7) | 3 (1.2) | 178 (72.4) | 0 (0.0) | 14 (5.7) | 4 (1.6)¶ | ALT elevation, dyspnoea, left ventricular dysfunction, fatigue, hypertension, vomiting, depressed mood, embolism, nausea, pericardial effusion, and small intestinal obstruction |
Placebo | PALETTE study 2011/2 | 123 | 123 (100) | 3 (2.4) | 0 (0) | 119 (96.7) | 0 (0.0) | 1 (0.8) | 0 (0.0) | Dyspnoea |
Trabectedin 1.5 mg/m2 q3w | Demetri 2009 | 136 | 128 (94.1) | 12 (8.8) | 2 (1.5) | 89 (65.4) | 2 (1.5) | 17 (12.5) | 6 (4.4)† | AEs leading to disconsolation were not reported |
Trabectedin 0.58 mg/m2 qw | Demetri 2009 | 134 | 134 (100) | 10 (7.5) | 3 (2.2) | 94 (70.1) | 0 (0.0) | 6 (4.5) | 21 (15.7)‡ | AEs leading to disconsolation were not reported |
Dacarbazine | GEIS study 2011 | 54 | 50 (92.6) | 2 (3.7) | - | 41 (75.9) | 0 (0.0) | - | 7 (13.0) | - |
Gemcitabine + Dacarbazine | GEIS study 2011 | 59 | 47 (79.7) | 0 (0.0) | - | 36 (61.0) | 0 (0.0) | 1 (1.7) | 10 (16.9) | - |
Gemcitabine | Pautier 2009 | 84* | - | 3 | - | - | - | - | - | AEs leading to disconsolation were not reported |
Gemcitabine + Docetaxel | Pautier 2009 | - | 9 | - | - | - | - | - | Hypersensitivity in one patient |
Non-randomised studies
Trial characteristics
Intervention | Dose | Study | N | STS subtypes (%) |
---|---|---|---|---|
Brostallicin | 10 mg/m2
| Leahy 2007 [33] | 43 | Multiple |
Cisplatin | 50 mg/m2
| Thigpen 1986 [34] | 20 | Leiomyosarcoma |
Cyclophosphamide | 1.5 g/m2
| 18 | NS | |
Dacarbazine | 1200 mg/m2
| Buesa 1991 [73] | 47 | Multiple |
Docetaxel | 100 mg/m2
| Kostler 2001 [37] | 25 | Multiple |
Docetaxel | 100 mg/m2
| Santoro 1999 [38] | 37 | Multiple |
Docetaxel | 100 mg/m2
| 21 | NS | |
Doxorubicin | 75 mg/m2
| Mouridsen 1987 [41] | 23 | NS |
Etoposide | 200-240 mg/m2/day | Crawley 1997 [42] | 17 | Multiple |
Etoposide | 130 mg/m2
| Dombernowsky 1987 [43] | 26 | NS |
Gefitinib | 500 mg | Ray-Coquard 2008 [44] | 48 | Synovial sarcoma≈ |
Gemcitabine | 1000 mg/m2
| Ferraresi 2008 [74] | 14 | Multiple |
Gemcitabine | 1000 mg/m2
| Hartmann 2006 [45] | 15 | Multiple |
Gemcitabine | 1000 mg/m2
| Look 2004 [75] | 35 | Leiomyosarcoma |
Gemcitabine | 200-250 mg/m2
| Spath-Schwalbe 2000 [46] | 18 | Multiple |
Ifosfamide | 2 g/m2 for 4d q3w | Antman 1985 [47] | 31 | Multiple |
Ifosfamide | 2 g/m2 for 4d q3w | Antman 1989 [48] | 94 | Multiple |
Ifosfamide | 1 g/m2 daily until Gr3 granulocytopenia q4w | Babovic 1998 [76] | 21 | Multiple |
Ifosfamide | 4 g/m2 for 3d q4w | 40 | Multiple | |
Ifosfamide | 4 g/m2 for 3d q4w | Nielsen 2000 [78] | 13 | NS |
Ifosfamide | 3.5 g/m2 for 4d q3w | Palumbo 1997 [79] | 38 | Multiple |
Ifosfamide | 4 g/m2 for 3.5d q3w | Patel 1997 [80] | 12 | Multiple |
Ifosfamide | 2g/m2 loading dose followed by 4g/m2 for 3d q3w | Patel 1997 [80] | 32 | Multiple |
Ifosfamide | 60 mg/kg for 5d q3-4w | Scheulen 1983 [81] | 16 | NS |
Liposomal doxorubicin | 55 mg/m2
| Skubitz 2003 [50] | 20 | Multiple |
Liposomal doxorubicin | 30-50 mg/m2
| Toma 2000 [51] | 25 | Multiple |
Methotrexate | 40 mg/m2
| Buesa 1984 [52] | 37 | NS |
Paclitaxel | 135-175 mg/m2
| Palumbo 1997 [53] | 12 | Multiple |
Paclitaxel | 200 mg/m2
| Patel 1997 [54] | 12 | Multiple |
Paclitaxel | 120 mg/m2
| Skubitz 1997 [55] | 17 | Multiple |
Sorafenib | 400 mg | 61 | Multiple | |
Sorafenib | 400 mg | Pacey 2011 [28] | 16 | Multiple |
Sunitinib | 50 mg | Decoster 2010 [58] | 24 | NS |
Trabectedin | 1.5 mg/m2
| 36 | Multiple | |
Trabectedin | 1.5 mg/m2
| Le Cesne 2005 [83] | 104 | Multiple |
Trabectedin | 1.5 mg/m2
| 27 | Multiple | |
Biricodar + doxorubicin | B - 120 mg1.5 mg/m2/hr; D – 60 mg/m2
| Bramwell 2002 [62] | 18 | Multiple |
Cisplatin + ifosfamide | C – 100 mg/m2 day 2&9; I −2.5 g/m2 for 3d | Budd 1993 [85] | 38 | Multiple |
Cisplatin + vinblastine | C – 50–100 mg/m2 day 1; V – 1.0-1.2 mg/m2 for 5d | Keohan 1997 [63] | 18 | Multiple |
D + IL-2 | D – 70 mg/m2; IL-2 - 18 MIU/m2
| Le Cesne 1999 [64] | 12 | NS |
Epirubicin + lonidamine | E – 120 mg/m2; I – 150–450 mg | Lopez 1995 [65] | 25 | Multiple |
Etoposide + ifosfamide | E – 200 mg/m2 for 3d; I – 1.5 g/m2 for 3d | Saeter 1995 [86] | 11 | NS |
Etoposide + ifosfamide | E – 50 mg/m2 for 8d; I - 1.5 g/m2 for 6d | Skubitz 1993 [87] | 16 | Multiple |
Gemcitabine + dacarbazine | G – 800–2160 mg/m2; DTIC – 500 mg/m2
| Buesa 2004 [66] | 22 | Multiple |
Gemcitabine + dacarbazine | G – 1800 mg/m2; DTIC – 500 mg/m2
| Losa 2007 [67] | 26 | Multiple |
Gemcitabine + docetaxel | G – 900 mg/m2; D – 100 mg/m2
| Hensley 2002 [88] | 16 | Leiomyosarcoma |
Gemcitabine + docetaxel | G – 900 mg/m2; D – 100 mg/m2
| Hensley 2008 [89] | 51 | Leiomyosarcoma |
Gemcitabine + docetaxel | G – 900 mg/m2; D – 100 mg/m2
| Montalar 2008 [68] | 12 | Multiple |
Methotrexate + vincristine | M – 5 g/m2; V – 1 mg/m2
| Vaughn 1984 [69] | 14 | NS |
VAC + IE | V – 2 mg; A – 70 mg/m2; C – 600 mg/m2; I – 1.8 g/m2; E – 500 mg/m2
| Palumbo 1998 [70] | 12 | NS |
C + VC + D + DTIC + IL-2 | IL-2 – 18 m units/d, followed by CYVADIC | Gravis 2001 [71] | 1 | Leiomyosarcoma |
D + I + DTIC + IL-2 | IL-2 – 18 m units/d, followed by D+I+DTIC | Gravis 2001 [71] | 9 | Multiple |
D + IL-2 | IL-2 – 18 m units/d, followed by D | Gravis 2001 [71] | 3 | Multiple |
Carboplatin + etoposide | C – 300 mg/m2; E – 300 mg/m2
| Holstein 1996 [72] | 8 | Multiple |
Dacarbazine | 1200 mg/m2
| Holstein 1996 [72] | 14 | Multiple |
Efficacy results
Intervention | Study | N | Response rate n (%), IRC or unclear | PFS | TTP in months | OS | DOR in months | Progressive disease | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ORR | CR | PR | MR | SD | n (%) or median (95% CI) | Median (range) | n (%) or median (range) | Median (range) | n (%), IRC or unclear | |||
Brostallicin | Leahy 2007 | 40 | 2 (5.0%)~ | 0 (0.0 %)~ | 2 (5.0%) ~ | - | 20 (50.0 %)~ | 3 mo: 18 (45.0%)~; 6 mo: 9 (22.5%)~
| 2.9 months~ (1.4 - 3.7) | 7.6 months (5.2 - 13.8) | - | 17 (42.5%)~ |
Cisplatin | Thigpen 1986 | 19 | 1 (5.3%) | 1 (5.3%) | 0 (0.0%) | - | 7 (36.8%) | - | - | - | 9 months (N = 1) | 11 (57.9%) |
Cyclophosphamide | Bramwell 1993 | 18 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - | - | - | - | - | - |
Dacarbazine | Buesa 1991 | 44 | 8 (18.2%) | 1 (2.3%) | 7 (15.9%) | - | 8 (18.2%) | - | - | - | - | 28 (63.6%) |
Docetaxel | Kostler 2001 | 25 | 4 (16.0%) | 0 (0.0%) | 4 (16.0%) | - | - | - | - | - | - | - |
Docetaxel | Santoro 1999 | 36 | 1 (2.8%)# | 0 (0.0%) | 1 (2.8%) | - | 10 (27.8%) | 1.4 months (N = 37) | - | 11.5 months (N = 37) | - | 25 (69.4%) |
Docetaxel | Van Hoesel 1994 | 21 | - | 0 (0.0%)~ | - | - | - | - | - | - | - | - |
Doxorubicin | Mouridsen 1987 | 23 | 2 (8.7%)~ | - | - | - | - | - | - | - | - | - |
Etoposide | Crawley 1997 | 16 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | 8 (50.0%) | - | - | 3.7 months (2.1 - 5.2)* (N = 17) | - | 8 (50.0%) |
Etoposide | Dombernowsky 1987 | 26 | - | - | 1 (3.8%) | - | - | - | - | - | 19 months (N = 1) | - |
Gefitinib | Ray-Coquard 2008 | 46 | 0 (0.0%)~ | 0 (0.0%)~ | 0 (0.0%)~ | 0 (0.0%)~ | 10 (21.7%)~ | 4 mo: 10 (21.7%)~; 6 mo: 3 (6.5%)~
| 1.4 months~ | - | - | 32 (69.6%)~ |
Gemcitabine | Ferraresi 2008 | 14 | 1 (7.1%) | 0 (0.0%) | 1 (7.1%) | - | 3 (21.4%) | - | 3.1 months (1.0 - 9.5) | 11.8 months (1.0 - 54.5) | 6.5 months (N = 1) | 10 (71.4%) |
Gemcitabine | Hartmann 2006 | 15 | 1 (6.7%) | 0 (0.0%) | 1 (6.7%) | - | 7 (46.7%) | 3 mo: 7 (46.7%); 6 mo: 2 (13.3%); 3.0 months (1.0 – 33.0) | 3 months | 6.0 months (3.0 - 33.0) | - | 7 (46.7%) |
Gemcitabine | Look 2004 | 33 | 7 (21.2%) | 1 (3.0%) | 6 (18.2%) | - | - | - | - | - | - | - |
Gemcitabine | Spath-Schwalbe 2000 | 18 | 2 (11.1%)# | 0 (0.0%) | 2 (11.1%) | - | 6 (33.3%) | - | - | 12 mo: 5 (27.8%); 8 months | 5.5 months (5.0 - 6.0) (N = 2) | 9 (50.0%) |
Ifosfamide | Antman 1985 | 26 | 8 (30.8%)# | 0 (0.0%) | 8 (30.8%) | 3 (11.5%) | 11 (42.3%) | - | - | - | (2.0 – 10.0+) (N = 11) | 4 (15.4%) |
Ifosfamide | Antman 1989 | 94 | 17 (18.1%) | 2 (2.1%) | - | - | - | - | - | - | - | - |
Ifosfamide | Babovic 1998 | 21 | 1 (4.8%) | 1 (4.8%) | 0 (0.0%) | - | 4 (19.0%) | - | - | - | - | 16 (76.2%) |
Ifosfamide | Le Cesne 1995 | 36 | 12 (33.3%) | 0 (0.0%) | 12 (33.3%) | - | 8 (22.2%) | - | - | 20.0 months (6.0 – 91.0+) (N = 40) | 8.0 months (6.0 – 13.0+) (N = 12) | 16 (44.4%) |
Ifosfamide | Nielsen 2000 | Unclear | 1 (7.7%)~ | 0 (0.0%) ~ | 1 (7.7%) ~ | - | - | - | - | - | - | - |
Ifosfamide | Palumbo 1997a | 38 | 15 (39.5%) | 1 (2.6%) | 14 (36.8%) | - | 17 (44.7%) | - | - | 13.0 months (6.0 – 30.0+) | 9.0 months (5.0 – 21.0+) (N = 15) | 6 (15.8) |
Ifosfamide | Patel 1997b | 11 | 5 (45.5%) | 0 (0.0%) | 5 (45.5%) | - | 2 (18.2%) | - | - | - | - | 4 (36.4%) |
Ifosfamide | Patel 1997b | 32 | 6 (18.8%) | 2 (6.3%) | 4 (12.5%) | - | - | - | - | - | - | - |
Ifosfamide | Scheulen 1983 | 16 | 10 (62.5%) | 2 (12.5%) | 3 (18.8%) | 5 (31.3%) | 1 (6.3%) | - | - | - | - | 5 (31.3%) |
Liposomal doxorubicin | Skubitz 2003 | 20 | 1 (5.0%)# | 1 (5.0%) | 0 (0.0%) | 3 (15.0%) | 3 (15.0%) | - | - | - | - | 12 (60.0%) |
Liposomal doxorubicin | Toma 2000 | 25 | 3 (12.0%) | 0 (0.0%) | 3 (12.0%) | 2 (8.0%) | 17 (68.0%) | - | - | 12.0 months (6.0 – 16.0+) | (3.0 – 9.0+) (N = 3) | 3 (12.0%) |
Methotrexate | Buesa 1984 | 21 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - | - | - | - | - | - |
Paclitaxel | Palumbo 1997b | 12 | 1 (8.3%)# | 0 (0.0%) | 1 (8.3%) | 1 (8.3%) | 6 (50.0%) | - | 3 months | 6 months | 4 months (N = 1) | 4 (33.3%) |
Paclitaxel | Patel 1997a | 12 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - | - | - | - | - | |
Paclitaxel | Skubitz 1997 | 15 | 1 (6.7%)# | 0 | 1 (6.7%) | - | - | - | - | - | 12 months (N = 1) | - |
Sorafenib | Bertuzzi 2010 | 61 | - | - | 9 (14.8%) | - | - | 6 mo: 20 (32.7%) | - | 6 mo: 41 (67.2%) (N = 61) | - | - |
Sorafenib | Bertuzzi 2010 | 30$ | 2 (6.7%)# | 1 (3.3%) | 1 (3.3%) | - | 18 (60.0%) | - | - | - | - | 10 (33.3%) |
Sorafenib | Pacey 2011 | 16 | - | - | - | - | 0 (0.0%) | - | - | - | - | - |
Sunitinib | Decoster 2010 | 20 | 1 (5.0%)# | 0 (0.0%) | 1 (5.0%) | - | 4 (20.0%) | - | - | - | 8.3 months (N =1) | 15 (75.0%) |
Trabectedin | Garcia-Carbonero 2004 | 36 | 3 (8.3%) | 1 (2.8%) | 2 (5.6%) | 2 (5.6%) | - | 12 mo: 4 (11.1%) | 1.7 months (1.3 - 4.4)* | 6 mo: 27 (75.0%); 12 mo: 19 (52.7%); 12.1 months (8.1 - 26.5)* | 9.0 months (4.0 – 20.0) (N = 3) | - |
Trabectedin | Le Cesne 2005 | 104 | 8 (8.7%)~ (N = 92) | 0 (0.0%) ~ (N = 92) | 8 (8.7%) ~(N = 92) | - | 44 (47.8%) ~† (N=92) | 3 mo: 54 (52%)~; 6 mo: 30 (29%)~; 9 mo: 21 (20%)~; 12 mo: 18 (17%)~ | 3.4 months (2.5 - 4.1)* ~ (N = 99) | 12 mo: 44 (42%); 9.1 months (7.8 - 12.1)* | 11.6 months~ (N = 8) | 35 (38.0%)~ (N = 92) |
Trabectedin | Yovine 2004 | 27 | 2 (7.4%) ~ | 0 (0.0%) ~ | 2 (7.4%) ~ | 2 (7.4%) ~ | 4 (14.8%) ~ | - | - | - | 12.2 months~ (N = 2) | - |
Biricodar + doxorubicin | Bramwell 2002 | 15 | 2 (13.3%) ~# | 0 (0.0%) ~ | 2 (13.3%) ~ | - | 7 (46.7%) ~ | 3.1 months~ (N = 15) | - | - | - | 6 (40.0%)~ |
Cisplatin + ifosfamide | Budd 1993 | 38 | 8 (21.0%) | 3 (7.9%) | 5 (13.2%) | - | - | - | - | 11 months | - | - |
Cisplatin + vinblastine | Keohan 1997 | 15 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | 7 (46.7%) | - | 2.0 months (0.7 - 12.0) (N =18) | - | - | 8 (53.3%) |
D + IL-2 | Le Cesne 1999 | 12 | 2 (16.7%) | 0 (0.0%) | 2 (16.7%) | - | - | - | - | - | - | - |
Epirubicin + lonidamine | Lopez 1995 | 24 | 2 (8.3%) | 0 (0.0%) | 2 (8.3%) | - | 1 (4.2%) | - | - | 14 months (N =24) | 6.5 months (N =2) | - |
Etoposide + ifosfamide | Saeter 1995 | 10 | 6 (60.0%) | 0 (0.0%) | 6 (60.0%) | - | - | - | - | - | - | - |
Etoposide + ifosfamide | Skubitz 1993 | 15 | 6 (40.0%) | 0 (0.0%) | 6 (40.0%) | - | 5 (33.3%) | - | - | - | (3.0 – 31.0+)~ (N = 6) | 4 (26.7%) |
Gemcitabine + dacarbazine | Buesa 2004 | 22 | 5 (26.3%) (N = 19) | 0 (0.0%) (N = 19) | 5 (26.3%) (N = 19) | - | 6 (31.6%) (N=19) | 3 mo: 9 (40.9%) (N = 22); 6 mo: 6 (27.3%) (N = 22) | - | - | 6.5 months (2.5 – 36.0) (N =5) | 8 (42.1%) (N = 19) |
Gemcitabine + dacarbazine | Losa 2007 | 23 | 1 (4.3%) | 1 (4.3%) | 0 (0.0%) | - | 11 (47.8%) | 3 mo: 12 (46.2%) (N = 26); 6 mo: 7 (26.9%) (N = 26) | 3.6 months (N = 23) | 8.5 months (N = 23) | - | 11 (47.8%) |
Gemcitabine + docetaxel | Hensley 2002 | 16 | 8 (50.0%) ~ | 1 (6.3%) ~ | 7 (43.8%) ~ | - | - | - | - | - | - | - |
Gemcitabine + docetaxel | Hensley 2008 | 48 | 13 (27.1%) | 3 (6.3%) | 10 (20.8%) | - | 24 (50.0%) | 3 mo: 35 (72.9%) (N = 48); 6 mo: 25 (52.1%) (N = 48); 6.7 months (0.7 – 27.0+) (N = 48) | - | 14.7 months (0.8 - 50.9+) (N = 48) | 9.0 months (3.9 - 24.5) (N = 13) | 8 (16.7%) |
Gemcitabine + docetaxel | Montalar 2008 | 12 | 1 (8.3%)# | 0 (0.0%) | 1 (8.3%) | - | 4 (33.3%) | - | - | - | - | 7 (58.3%) |
Methotrexate + vincristine | Vaughn 1984 | 14 | 2 (14.3%) | 0 (0.0%) | 2 (14.3%) | - | 3 (21.4%) | - | - | - | - | - |
VAC + IE | Palumbo 1998 | 12 | 3 (25.0%) | 0 (0.0%) | 3 (25.0%) | - | 4 (33.3%) | - | - | - | - | 3 (25.0%) |
C + VC + D + DTIC + IL-2 | Gravis 2001 | 1 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | - | - | - | - | - | 1 (100%) |
D + I + DTIC + IL-2 | Gravis 2001 | 9 | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - | 1 (11.1%) | - | - | - | - | 8 (88.9%) |
D + IL-2 | Gravis 2001 | 3 | 1 (33.3%) | 0 (0.0%) | 1 (33.3%) | - | - | - | - | - | 2.0 months (N = 1) | 2 (66.7%) |
Carboplatin + etoposide | Holstein 1996 | 8 | 0 (0.0%)# | 0 (0.0%) | 0 (0.0%) | - | 2 (25.0%)† | - | - | 12.0 months (4.0 – 25.0) | - | 6 (75.0%) |
Dacarbazine | Holstein 1996 | 14 | 0 (0.0%)# | 0 (0.0%) | 0 (0.0%) | - | 2 (14.3%) † | - | - | 5.0 months (1.0 – 11.0) | - | 12 (85.7%) |